Novo Nordisk plunges 8.2% premarket as Ciltibekimap phase 3 fails

1. 1Novo Nordisk (NVO) dives premarket after its Ciltibekimap phase 3 trial failed to show a significant reduction in major cardiovascular events versus placebo
2. 2The experimental therapy demonstrated biological activity but missed its primary endpoint, sending shares down 8.2% in premarket trading
3. 3The five-day winning streak is expected to end, with losses likely turning shares negative year-to-date and year-over-year if the decline holds

Source Schaeffer's Research +8 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →